Clinical Trial

A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical research study is to find the recommended safe dose of TGFBR2 KO CAR27/IL-15 NK cells that can be given to patients with relapsed/refractory disease. The safety and effectiveness of this treatment will also be studied.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-04-09; most recent amendment 2026-05-05.
Status change: Not Yet Recruiting → Recruiting 2025-09-18
Trial Details
NCT Number NCT06930651
Lead Sponsor M.D. Anderson Cancer Center
Conditions Myeloid Malignancies
Enrollment 42 participants
Start Date 2025-09-03
Primary Completion 2028-05-01 (estimated)
Study Completion 2030-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-06